Li Lv1,2,3,4,5, Fang Wang1,2,3,4, Liang Wu1,2,3,4, Jin-Wei Wang1,2,3,4, Zhao Cui1,2,3,4, Salim S Hayek6, Changli Wei6, Jochen Reiser6, Kevin He7, Luxia Zhang1,2,3,4,8, Min Chen1,2,3,4, Ming-Hui Zhao1,2,3,4. 1. Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China. 2. Institute of Nephrology, Peking University, Beijing, China. 3. Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China. 4. Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China. 5. The First Affiliated Hospital of Baotou Medical College, Baotou, China. 6. Department of Medicine, Rush University Medical Center, Chicago, IL, USA. 7. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA. 8. Center for Data Science in Health and Medicine, Peking University, Beijing, China.
Abstract
BACKGROUND: Soluble urokinase-type plasminogen activator receptor (suPAR), a marker of immune activation, was shown to be associated with outcomes and kidney disease among various patient populations. The prognostic role of circulating suPAR levels in patients with chronic kidney disease (CKD) needs to be investigated in a cohort with large sample size of renal diseases. METHODS: We measured serum suPAR concentration in 2391 CKD patients in the multicenter Chinese Cohort Study of Chronic Kidney Disease, and investigated the association of serum suPAR with the prespecified endpoint event, end-stage renal disease (ESRD), using Cox proportional hazards regression model. RESULTS: Altogether, 407 ESRD events occurred during the median follow-up of 54.8 (interquartile range: 47.5-62.2) months. The higher levels of serum suPAR were independently associated with increased risk of incident ESRD after adjusting for potential confounders including the baseline estimated glomerular filtration rate categories, with the hazard ratios (HRs) of 1.53 [95% confidence intervals (CIs) 1.10-2.12] for the top tertile (≥3904 pg/mL) compared with the bottom tertile (<2532 pg/mL). When stratified by the etiologies of CKD, among patients with glomerulonephritis (GN), serum suPAR levels were also independently associated with the higher risk of ESRD, with an HR of 1.61 (95% CI 1.03-2.53) in the top tertile compared with the bottom tertile. CONCLUSIONS: Circulating suPAR level was independently associated with an increased risk of progression to ESRD in Chinese CKD patients, especially in those with an etiology of GN.
BACKGROUND: Soluble urokinase-type plasminogen activator receptor (suPAR), a marker of immune activation, was shown to be associated with outcomes and kidney disease among various patient populations. The prognostic role of circulating suPAR levels in patients with chronic kidney disease (CKD) needs to be investigated in a cohort with large sample size of renal diseases. METHODS: We measured serum suPAR concentration in 2391 CKD patients in the multicenter Chinese Cohort Study of Chronic Kidney Disease, and investigated the association of serum suPAR with the prespecified endpoint event, end-stage renal disease (ESRD), using Cox proportional hazards regression model. RESULTS: Altogether, 407 ESRD events occurred during the median follow-up of 54.8 (interquartile range: 47.5-62.2) months. The higher levels of serum suPAR were independently associated with increased risk of incident ESRD after adjusting for potential confounders including the baseline estimated glomerular filtration rate categories, with the hazard ratios (HRs) of 1.53 [95% confidence intervals (CIs) 1.10-2.12] for the top tertile (≥3904 pg/mL) compared with the bottom tertile (<2532 pg/mL). When stratified by the etiologies of CKD, among patients with glomerulonephritis (GN), serum suPAR levels were also independently associated with the higher risk of ESRD, with an HR of 1.61 (95% CI 1.03-2.53) in the top tertile compared with the bottom tertile. CONCLUSIONS: Circulating suPAR level was independently associated with an increased risk of progression to ESRD in Chinese CKD patients, especially in those with an etiology of GN.
Authors: Franz Schaefer; Howard Trachtman; Elke Wühl; Marietta Kirchner; Salim S Hayek; Ali Anarat; Ali Duzova; Sevgi Mir; Dusan Paripovic; Alev Yilmaz; Francesca Lugani; Klaus Arbeiter; Mieczyslaw Litwin; Jun Oh; Maria Chiara Matteucci; Jutta Gellermann; Simone Wygoda; Augustina Jankauskiene; Günter Klaus; Jiri Dusek; Sara Testa; Aleksandra Zurowska; Alberto Caldas Afonso; Melissa Tracy; Changli Wei; Sanja Sever; William Smoyer; Jochen Reiser Journal: JAMA Pediatr Date: 2017-11-06 Impact factor: 16.193
Authors: Tae-Hyun Yoo; Christopher E Pedigo; Johanna Guzman; Mayrin Correa-Medina; Changli Wei; Rodrigo Villarreal; Alla Mitrofanova; Farah Leclercq; Christian Faul; Jing Li; Matthias Kretzler; Robert G Nelson; Markku Lehto; Carol Forsblom; Per-Henrik Groop; Jochen Reiser; George William Burke; Alessia Fornoni; Sandra Merscher Journal: J Am Soc Nephrol Date: 2014-06-12 Impact factor: 10.121
Authors: Gethin W Hodges; Casper N Bang; Kristian Wachtell; Jesper Eugen-Olsen; Jørgen L Jeppesen Journal: Can J Cardiol Date: 2015-03-25 Impact factor: 5.223
Authors: S Florquin; J G van den Berg; D P Olszyna; N Claessen; S M Opal; J J Weening; T van der Poll Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew Levey; Paul de Jong; Ron T Gansevoort; Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Ron T Gansevoort; Andrew Levey; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Toshiharu Ninomiya; John Chalmers; Stephen Macmahon; Marcello Tonelli; Brenda Hemmelgarn; Frank Sacks; Gary Curhan; Allan J Collins; Suying Li; Shu-Cheng Chen; K P Hawaii Cohort; Brian J Lee; Areef Ishani; James Neaton; Ken Svendsen; Johannes F E Mann; Salim Yusuf; Koon K Teo; Peggy Gao; Robert G Nelson; William C Knowler; Henk J Bilo; Hanneke Joosten; Nanno Kleefstra; K H Groenier; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley Journal: Kidney Int Date: 2011-02-09 Impact factor: 10.612
Authors: Stig Lyngbæk; Jacob L Marott; Daniél V Møller; Michael Christiansen; Kasper K Iversen; Peter M Clemmensen; Jesper Eugen-Olsen; Jørgen L Jeppesen; Peter R Hansen Journal: Am J Cardiol Date: 2012-09-13 Impact factor: 2.778
Authors: Ron T Gansevoort; Ricardo Correa-Rotter; Brenda R Hemmelgarn; Tazeen H Jafar; Hiddo J Lambers Heerspink; Johannes F Mann; Kunihiro Matsushita; Chi Pang Wen Journal: Lancet Date: 2013-05-31 Impact factor: 79.321
Authors: Tuula K Outinen; Laura Tervo; Satu Mäkelä; Reetta Huttunen; Niina Mäenpää; Heini Huhtala; Antti Vaheri; Jukka Mustonen; Janne Aittoniemi Journal: PLoS One Date: 2013-08-21 Impact factor: 3.240
Authors: Matthew Schenk; Fabian Eichelmann; Matthias B Schulze; Natalia Rudovich; Andreas F Pfeiffer; Romina di Giuseppe; Heiner Boeing; Krasimira Aleksandrova Journal: Biomark Med Date: 2019-06-03 Impact factor: 2.851
Authors: Clemens Höbaus; Martin Ursli; Sarah Mohammed Yussef; Thomas Wrba; Renate Koppensteiner; Gerit-Holger Schernthaner Journal: Vasc Med Date: 2021-01-15 Impact factor: 3.239
Authors: Sarah J Schrauben; Haochang Shou; Xiaoming Zhang; Amanda Hyre Anderson; Joseph V Bonventre; Jing Chen; Steven Coca; Susan L Furth; Jason H Greenberg; Orlando M Gutierrez; Joachim H Ix; James P Lash; Chirag R Parikh; Casey M Rebholz; Venkata Sabbisetti; Mark J Sarnak; Michael G Shlipak; Sushrut S Waikar; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Jeffrey R Schelling Journal: J Am Soc Nephrol Date: 2020-10-29 Impact factor: 14.978